Dr. Stephen Freedland, MD
Claim this profileCedars-Sinai Medical Center
Affiliated Hospitals
Cedars-Sinai Medical Center
Clinical Trials Stephen Freedland, MD is currently running
Keto Diet vs Standard Cancer Diet
for Glioblastoma
This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.
Recruiting
0 awards
Phase 2
Fasting-Mimicking Diet
for Prostate Cancer
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimicking diet (5 days per month eating L-Nutra products only for 6 months) vs. usual diet on response to cancer treatment of metastatic castrate sensitive prostate adenocarcinoma.
Recruiting
0 awards
Phase 2
More about Stephen Freedland, MD
Clinical Trial Related
3 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Stephen Freedland, MD has experience with
- Biopsy
- Biospecimen Collection
- Placebo Administration
- Urolithin A Supplement
- Walnuts
- RISE (Reinvent, Integrate, Strengthen, Expand) Intervention
Breakdown of trials Stephen Freedland, MD has run
Prostate Cancer
Prostate Adenocarcinoma
Cancer
Survivorship
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephen Freedland, MD specialize in?
Stephen Freedland, MD focuses on Prostate Cancer and Prostate Adenocarcinoma. In particular, much of their work with Prostate Cancer has involved treating patients, or patients who are undergoing treatment.
Is Stephen Freedland, MD currently recruiting for clinical trials?
Yes, Stephen Freedland, MD is currently recruiting for 4 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Stephen Freedland, MD has studied deeply?
Yes, Stephen Freedland, MD has studied treatments such as Biopsy, Biospecimen Collection, Placebo Administration.
What is the best way to schedule an appointment with Stephen Freedland, MD?
Apply for one of the trials that Stephen Freedland, MD is conducting.
What is the office address of Stephen Freedland, MD?
The office of Stephen Freedland, MD is located at: Cedars-Sinai Medical Center, Los Angeles, California 90048 United States. This is the address for their practice at the Cedars-Sinai Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.